StopDown
Zumutor Biologics logo
Funding · 13 June 2026Zumutor Biologics$7.3 Mn (₹70 Cr)Develops immunotherapy drugs for cancerzumutor.com ↗

Zumutor Biologics raises $7.3 million in Pre-Series B funding

By · Editor ·

Series BBengaluruFounded 2013
  • Zumutor develops immunotherapy drugs that activate natural killer cells to attack tumours
  • The company raised $7.3 million in Pre-Series B funding from Premji Invest, Accel, Bharat Innovation Fund, and angels Ashish Kacholia and Raj Dandu
  • Funds will support global Phase 2 studies of its lead drug ZM008 starting in India

What happened

  • Zumutor Biologics has raised $7.3 million in a new funding round.
  • The investment was led by Premji Invest, a new participant in the deal.
  • Existing investors Accel and Bharat Innovation Fund also participated in this round.
  • Angel investors Ashish Kacholia and Raj Dandu joined the funding as well.
  • The company plans to complete US FDA Phase 1 clinical studies of its drug ZM008.
  • Funds will initiate Phase 1B expansion cohorts and global Phase 2 studies including in India.
  • This follows an earlier Series A4 round of $6.2 million in 2021.
  • Human trials for ZM008 began in 2024 showing early signals in difficult-to-treat tumour types.

Why it matters

  • The funding supports the company's push into global Phase 2 clinical studies.
  • It aligns with the government's biopharma SHAKTI scheme worth ₹10,000 crore.
  • India's bioeconomy is projected to reach $300 billion by 2030.

The business

  • Zumutor develops immunotherapy drugs that activate natural killer cells to attack tumours.
  • Its lead program is ZM008, described as a first-in-class NK cell checkpoint therapy.
  • The company utilizes two proprietary Antibody Engineering Platforms targeting innate immunity.
  • These platforms specifically target the tumor microenvironment to enhance drug efficacy.
  • The company is headquartered in the US with an R&D laboratory in Bengaluru.
  • Founding CEO Kavitha Iyer Rodrigues leads the company since its establishment in 2013.
  • Chief Scientific Officer Maloy Ghosh oversees the scientific development of therapies.
  • The company focuses on treating difficult-to-treat tumour types through innovative mechanisms.

The founders

Kavitha Iyer Rodrigues

Founder and CEO
  • Founded Zumutor Biologics in 2013.
  • Leads the company's strategic direction and operations.
  • Oversees the development of immunotherapy drugs.

Who put in money

  • Premji Invest lead — New investor participating in the Series B round.
  • Accel existing — Existing investor continuing support in the current round.
  • Bharat Innovation Fund existing — Existing investor participating in the funding round.

In numbers

₹4.6 CrTotal Revenue FY25 · 2025
₹8.6 CrTotal Expenses FY25 · 2025
₹-3.9 CrProfit After Tax FY25 · 2025
-84.2%Net Profit Margin FY25 · 2025
₹58.6 CrTotal Assets FY25 · 2025

What happens next

  • Complete US FDA Phase 1 clinical study of ZM008 monotherapy and combination regimens.
  • Initiate Phase 1B expansion cohorts for further clinical evaluation.
  • Launch global Phase 2 studies including trials in India.

Earlier rounds

  • 2021 · Series A4 · $6.2 Mn · led by Siana Capital

Up against

StrainX BioworksCellogen Therapeutics

Words to know

Immunotherapy
Treatment that uses the body's immune system to fight diseases like cancer.
Natural Killer (NK) Cells
A type of white blood cell that attacks tumours and infected cells.
Phase 1 Clinical Study
Early-stage research testing safety and dosage in humans.
First-in-class
A drug with a novel mechanism of action not seen before.

The numbers around it

Healthcare & Life Sciences in June 2026: 11 rounds with a disclosed amount, $118 million in all; the biggest was Vetic ($40 Mn). Every sector this year →

Other articles talking about it

Read it as a card in the app

Terms in this story

  • Funding stage: Startups raise money in steps called funding stages: pre-seed, seed, Series A, B, C and later, ending in a listing or a sale. Each step is larger and asks for more proof. In India, Series A rounds run from a few million dollars to about $15 million, as of November 2026.
  • Series B/C: Series B, C, D and later rounds are growth rounds: large cheques for a startup with a proven model that wants to expand, enter new markets or move toward profit and a listing. In India they are usually priced in CCPS and, when foreign investors take part, must follow FEMA pricing rules.

Everything on Zumutor Biologics → · All startup news on 13 June 2026 →

Is this Zumutor Biologics? Get your “Featured on StopDown” badge →